Disseminated intravascular coagulation in obstetric disorders and its acute haematological management

Blood Reviews

Volumn 23, Issue 4, 2009, Pages 167-176

  Thachil, Jecko ^a   Toh, Cheng Hock ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Coagulation; Disseminated intravascular coagulation; Fibrinolysis; Obstetrics; Placenta; Pregnancy; Thrombin

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING INHIBITOR; DROTRECOGIN; FIBRINOGEN; FIBRINOPEPTIDE A; HEPARIN; PHOSPHOLIPID; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBOPLASTIN;

ACUTE DISEASE; AMNION FLUID EMBOLISM; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTINUOUS INFUSION; CRYOPRECIPITATE; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FATTY LIVER; FETUS DEATH; FIBRINOGEN BLOOD LEVEL; FIBRINOGEN DEFECT; FIBRINOLYSIS; HELLP SYNDROME; HEMOSTASIS; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; INTRAUTERINE INFECTION; PATHOGENESIS; PATHOPHYSIOLOGY; PLACENTA PREVIA; PLACENTAL DELIVERY; POSTPARTUM HEMORRHAGE; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SEPTIC ABORTION; SOLUTIO PLACENTAE; SYNCYTIOTROPHOBLAST; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ANTICOAGULANTS; BLOOD COAGULATION FACTORS; BLOOD COMPONENT TRANSFUSION; DISSEMINATED INTRAVASCULAR COAGULATION; FACTOR VIIA; FEMALE; HUMANS; OBSTETRIC LABOR COMPLICATIONS; PLACENTA; POSTPARTUM HEMORRHAGE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOPLASTIN;

EID: 67349246760     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2009.04.002     Document Type: Article

References (115)

1. Dutt T., and Toh C.H. The Yin-Yang of thrombin and activated protein C. Br J Haematol 140 (2008) 505-515
2. Rittirsch D., Flierl M.A., and Ward P.A. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 8 (2008) 776-787
3. Letsky E.A. Disseminated intravascular coagulation. Best Pract Res Clin Obstet Gynaecol. 15 (2001) 623-644
4. Clark S.L., Hankins G., Dudley D.A., et al. Amniotic fluid embolism: analysis of the national registry. Am J Obstet Gynecol 172 (1995) 1158-1167
5. Davies S. Amniotic fluid embolus: a review of the literature. Can J Anaesth 48 (2001) 88-98
6. Pritchard J.A. Fetal death in utero. Obstet Gynecol 14 (1959) 573-580
7. Jimenez J.M., and Pritchard J.A. Pathogenesis and treatment of coagulation defects resulting from fetal death. Obstet Gynecol 32 (1968) 449-459
8. Petersen I.R., and Nyholm H.C. Multiple pregnancies with single intrauterine demise. Acta Obstet Gynecol Scand 78 (1999) 202-206
9. Sibai B., Dekker G., and Kupferminc M. Pre-eclampsia. Lancet 365 (2005) 785-799
10. Dekker G.A. Surgically obtained sperm and risk of gestational hypertension and pre-eclampsia. Lancet 359 (2002) 673-674
11. Ishihara N., Matsuo H., Murakoshi H., et al. Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol 186 (2002) 158-166
12. Redman C.W., Sacks G.P., and Sargent I.L. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 180 (1999) 499-506
13. Savvidou M.D., Hingorani A.D., Tsikas D., et al. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 361 (2003) 1511-1517
14. Redman C.W. Platelets and the beginnings of preeclampsia. N Engl J Med 323 (1990) 478-480
15. Oyelese Y., and Ananth C.V. Placental abruption. Obstet Gynecol 108 (2006) 1005-1016
16. De Lee J.B. A case of fatal hemorrhagic diathesis, with premature detachment of the placenta. Am J Obstet Dis Women Child 44 (1901) 785-792
17. Kramer M.S., Usher R.H., Pollack R., et al. Etiologic determinants of abruptio placentae. Obstet Gynecol 89 (1997) 221-226
18. Steinborn A., Seidl C., Sayehli C., et al. Anti-fetal immune response mechanisms may be involved in the pathogenesis of placental abruption. Clin Immunol 110 (2004) 45-54
19. Ananth C.V., Getahun D., Peltier M.R., et al. Placental abruption in term and preterm gestations: evidence for heterogeneity in clinical pathways. Obstet Gynecol 107 (2006) 785-792
20. Rana A., Sawhney H., Gopalan S., et al. Abruptio placentae and chorioamnionitis -microbiological and histologic correlation. Acta Obstet Gynecol Scand 78 (1999) 363-366
21. Weiner C.P. The obstetric patient and disseminated intravascular coagulation. Clin Perinatol 13 (1986) 705-717
22. Hess J.R. Blood and coagulation support in trauma care. Hematol Am Soc Hematol Educ Program 2007 (2007) 187-191
23. Schouten M., Wiersinga W.J., Levi M., et al. Inflammation, endothelium, and coagulation in sepsis. J Leukocyte Biol 83 (2008) 536-545
24. Martin J.N., Rose C.H., and Briery C.M. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol 195 (2006) 914-934
25. Fang C.J., Richards A., Liszewski M.K., et al. Advances in understanding of pathogenesis of aHUS and HELLP. Br J Haematol 143 (2008) 336-348
26. Bacq Y. Acute fatty liver of pregnancy. Semin Perinatol 22 (1998) 134-140
27. Castro M.A., Goodwin M.T., Shaw K.J., et al. Disseminated intravascular coagulation and antithrombin III depression in acute fatty liver of pregnancy. Am J Obstet Gynecol 174 (1996) 211-216
28. Hoffman M., and Monroe D.M. Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am 21 (2007) 1-11
29. Oliver J, Monroe D, Roberts H, et al. Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol 1999;19:170-7.
30. Esmon C.T., Esmon N.L., and Harris K.W. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 257 (1982) 7944-7947
31. Pérez-Casal M., Downey C., Fukudome K., et al. Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood 105 (2005) 1515-1522
32. Kalafatis M., Rand M.D., and Mann K.G. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 269 (1994) 31869-31880
33. Bajaj M.S., Birktoft J.J., Steer S.A., et al. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 86 (2001) 959-972
34. Medved L., and Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost 89 (2003) 409-419
35. Bajzar L., Morser J., and Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 271 (1996) 16603-16608
36. Nesheim M.E., Tracy R.P., and Mann K.G. 'Clotspeed', a mathematical simulation of the functional properties of prothrombinase. J Biol Chem 259 (1984) 1447-1453
37. Giles A.R., Mann K.G., and Nesheim M.E. A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol 69 (1988) 491-497
38. Giles A.R., Nesheim M.E., and Mann K.G. Studies of factors V and VIII:C in an animal model of disseminated intravascular coagulation. J Clin Invest 74 (1984) 2219-2225
39. Smirnov M.D., and Esmon C.T. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 269 (1994) 816-819
40. Rosing J., van Rijn J.L., Bevers E.M., et al. The role of activated human platelets in prothrombin and factor X activation. Blood 65 (1985) 319-332
41. Moyer M.P., Tracy R.P., Tracy P.B., et al. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol 18 (1998) 458-465
42. Bretelle F., Sabatier F., Desprez D., et al. Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost 89 (2003) 486-492
43. Cabana V.G., Siegel J.N., and Sabesin S.M. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res 30 (1989) 39-49
44. Dennis M.W., Downey C., Brufatto N., et al. Prothrombinase enhancement through quantitative and qualitative changes affecting very low density lipoprotein in complex with C-reactive protein. Thromb Haemost 9 (2004) 522-530
45. Griffin J.H., Kojima K., Banka C.L., et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 103 (1999) 219-227
46. Sattar N., Bendomir A., Berry C., et al. Lipoprotein subfraction concentrations in preeclampsia: pathogenic parallels to atherosclerosis. Obstet Gynecol 89 (1997) 403-408
47. Reverdiau P., Jarousseau A.C., Thibault G., et al. Tissue factor activity of syncytiotrophoblast plasma membranes and tumoral trophoblast cells in culture. Thromb Haemost 73 (1995) 49-54
48. Aharon A., Brenner B., Katz T., et al. Tissue factor and tissue factor pathway inhibitor levels in trophoblast cells: implications for placental hemostasis. Thromb Haemost 92 (2004) 776-786
49. Pedersen B., Holscher T., Sato Y., et al. A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice. Blood 105 (2005) 2777-2782
50. Brenner B. Haemostatic changes in pregnancy. Thromb Res 114 (2004) 409-414
51. Boffa M.C., Valsecchi L., Fausto A., et al. Predictive value of plasma thrombomodulin in preeclampsia and gestational hypertension. Thromb Haemost 79 (1998) 1092-1095
52. Isermann B, Sood R, Pawlinski R, et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 2003;9:331-7.
53. Gu J.M., Crawley J.T., Ferrell G., et al. Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. J Biol Chem 277 (2002) 43335-43343
54. Hurtado V., Montes R., Gris J.C., et al. Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for foetal death. Blood 104 (2004) 1369-1374
55. Clark P., Brennand J., Conkie J.A., et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 79 (1998) 1166-1170
56. Comp P.C., Thurnau G.R., Welsh J., et al. Functional and immunologic protein S levels are decreased during pregnancy. Blood 68 (1986) 881-885
57. Cumming A.M., Tait R.C., Fildes S., et al. Development of resistance to activated protein C during pregnancy. Br J Haematol 90 (1995) 725-727
58. Bremme K., Ostlund E., Almqvist I., et al. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet Gynecol 80 (1992) 132-137
59. Cerneca F., Ricci G., Simeone R., et al. Coagulation and fibrinolysis changes in normal pregnancy. Eur J Obstet Gynecol Reprod Biol 73 (1997) 31-36
60. van Wersch J.W., and Ubachs J.M. Blood coagulation and fibrinolysis during normal pregnancy. Eur J Clin Chem Clin Biochem 29 (1991) 45-50
61. Robb A.O., Mills N.L., Din J.N., et al. Acute endothelial tissue plasminogen activator release in pregnancy. J Thromb Haemost 7 (2009) 138-142
62. Toh C.H. Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction. Blood Coagul Fibrin 14 Suppl 1 (2003) S69-S71
63. Chabloz P., Reber G., Boehlen F., et al. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haematol 115 (2001) 150-152
64. Mousa H.A., Downey C., Alfirevic Z., et al. Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy. Thromb Haemost 92 (2004) 1025-1031
65. Das M., Xu B., Lin L., et al. Phosphatidylserine efflux and intercellular fusion in a BeWo model of human villous cytotrophoblast. Placenta 25 (2004) 396-407
66. Katsuragawa H., Rote N.S., Inoue T., et al. Monoclonal antiphosphatidylserine antibody reactivity against human first-trimester placental trophoblasts. Am J Obstet Gynecol 172 (1995) 1592-1597
67. O'Riordan M.N., and Higgins J.R. Haemostasis in normal and abnormal pregnancy. Best Pract Res Clin Obstet Gynaecol 17 (2003) 385-396
68. Wallenburg H.C., and van Kessel P.H. Platelet lifespan in normal pregnancy as determined by a non-radioisotopic technique. BJOG 85 (1978) 33-36
69. Neame P.B., Kelton J.G., Walker I.R., et al. Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation. Blood 56 (1980) 88-92
70. Levi M., ten Cate H., and van der Poll T. Disseminated intravascular coagulation: state of the art. Thromb Haemost 82 (1999) 695-705
71. Manten G.T., Franx A., Sikkema J.M., et al. Fibrinogen and high molecular weight fibrinogen during and after normal pregnancy. Thromb Res 114 (2004) 19-23
72. Charbit B., Mandelbrot L., Samain E., et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 5 (2007) 266-273
73. Nieuwenhuizen W. A reference material for harmonisation of D-dimer assays. Thromb Haemost 77 (1997) 1031-1033
74. Taylor Jr. F.B., Toh C.H., Hoots K., et al. Towards a definition, clinical and laboratory criteria and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86 (2001) 1027-1030
75. Toh C.H., and Hoots W.K. The scoring system of the SSC on DIC of the ISTH: a 5-year overview. J Thromb Haemost 5 (2007) 604-606
76. Boisclair M.D., Ireland H., and Lane D.A. Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Rev 4 (1990) 25-40
77. Cadroy Y., Grandjean H., Pichon J., et al. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynaecol 100 (1993) 416-420
78. Halligan A., Bonnar J., Sheppard B., et al. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. Br J Obstet Gynaecol 101 (1994) 488-492
79. Weiner C.P. The mechanism of reduced antithrombin III activity in women with preeclampsia. Obstet Gynecol 72 (1988) 847-849
80. Magriples U., Chan D.W., Bruzek D., et al. Thrombomodulin: a new marker for placental abruption. Thromb Haemost 81 (1999) 32-34
81. Franchi F., Biguzzi E., Cetin I., et al. Mutations in the thrombomodulin and endothelial protein C receptor genes in women with late fetal loss. Br J Haematol 114 (2001) 641-646
82. Kaare M., Ulander V.M., Painter J.N., et al. Variations in the thrombomodulin and endothelial protein C receptor genes in couples with recurrent miscarriage. Hum Reprod 22 (2007) 864-868
83. Estellés A., Gilabert J., Grancha S., et al. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia. Thromb Haemost 79 (1998) 500-508
84. Chappell L.C., Seed P.T., Briley A., et al. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 187 (2002) 127-136
85. Antovic J.P., Rafik Hamad R., et al. Does thrombin activatable fibrinolysis inhibitor contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?. Thromb Haemost 88 (2002) 644-647
86. He S., Bremme K., and Blombäck M. A laboratory method for determination of overall haemostatic potential in plasma. I. Method design and preliminary results. Thromb Res 96 (1999) 145-156
87. VanWijk M.J., Nieuwland R., and Boer K. Microparticle subpopulations are increased in preeclampsia: possible involvement in vascular dysfunction?. Am J Obstet Gynecol 187 (2002) 450-456
88. Redman C.W., and Sargent I.L. Circulating microparticles in normal pregnancy and pre-eclampsia. Placenta 29 Suppl. A (2008) S73-S77
89. Higgins J.R., Walshe J.J., Darling M.R., et al. Hemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies. Am J Obstet Gynecol 179 (1998) 520-526
90. Josic D., Hoffer L., Buchacher A., et al. Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity. Thromb Res 100 (2000) 433-441
91. Preston F.E., Laidlaw S.T., Sampson B., et al. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 116 (2002) 619-624
92. Kreuz W., Meili E., Peter-Salonen K., et al. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apher Sci 32 (2005) 247-253
93. Haas T., Fries D., Velik-Salchner C., et al. Fibrinogen in craniosynostosis surgery. Anesth Analg 106 (2008) 725-731
94. Weinkove R., and Rangarajan S. Fibrinogen concentrate for acquired hypofibrinogenaemic states. Transfus Med 18 (2008) 151-157
95. Corrigan Jr. J.J., and Jordan C.M. Heparin therapy in septicemia with disseminated intravascular coagulation. N Engl J Med 283 (1970) 778-782
96. Feinstein D.I. Treatment of disseminated intravascular coagulation. Semin Thromb Hemost 14 (1988) 351-362
97. Kobayashi T., Terao T., Ikenoue T., et al. BI51017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Semin Thromb Hemost 29 (2003) 645-652
98. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699-709
99. Kobayashi T, Terao T, Maki M, et al. Activated protein C is effective for disseminated intravascular coagulation associated with placental abruption. Thromb Haemost 1999;82:1363.
100. Wise A., and Clark V. Strategies to manage major obstetric haemorrhage. Curr Opin Anaesthesiol 21 (2008) 281-287
101. Jansen A.J., van Rhenen D.J., Steegers E.A., et al. Postpartum hemorrhage and transfusion of blood and blood components. Obstet Gynecol Surv 60 (2005) 663-671
102. Stainsby D., MacLennan S., Thomas D., Isaac J., and Hamilton P.J. BCSH guidelines on the management of massive blood loss. Br J Haematol 135 (2006) 634-641
103. Van der Linden P., and Ickx B.E. The effects of colloid solutions on hemostasis. Can J Anaesth 53 Suppl. 6 (2006) S30-S39
104. Hirshberg A., Dugas M., Banez E., Scott B., Wall M., and Mattox K. Minimizing dilutional coagulopathy in exanguinating hemorrhage: a computer simulation. J Trauma 54 (2003) 454-461
105. Malone D.L., Hess J.R., and Fingerhut A. Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. J Trauma 60 Suppl. 6 (2006) S91-S96
106. Borgman M.A., Spinella P.C., Perkins J.G., et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 63 (2007) 805-813
107. Johansson P.I., Stensballe J., Rosenberg I., et al. Proactive administration of platelets and plasma for patients with a ruptured abdominal aortic aneurysm: evaluating a change in transfusion practice. Transfusion 47 (2007) 593-598
108. Fenger-Eriksen C., Lindberg-Larsen M., Christensen A.Q., et al. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth 101 (2008) 769-773
109. Meng Z.H., Wolberg A.S., Monroe III D.M., et al. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 55 (2003) 886-891
110. Gabriel A., Li X., Monroe D.M., et al. Recombinant human factor VIIa, (rFVIIa) can activate FX on activated platelets. J Thromb Haemost 2 (2004) 1816-1822
111. Sobieszczyk S., Breborowicz G.H., Platicanov V., et al. Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical use. Acta Obstet Gynecol Scand 85 (2006) 1239-1247
112. Franchini M., Lippi G., and Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. Br J Obstet Gynaecol 114 (2007) 8-15
113. Haynes J., Laffan M., and Plaat F. Use of recombinant activated factor VII in massive obstetric haemorrhage. Int J Obstet Anesth 16 (2007) 40-49
114. Payne E.M., Brett S.J., and Laffan M.A. Efficacy of recombinant activated factor VII in unselected patients with uncontrolled haemorrhage: a single centre experience. Blood Coagul Fibrin 17 (2006) 397-402
115. Searle E., Pavord S., and Alfirevic Z. Recombinant factor VIIa and other pro-haemostatic therapies in primary postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol 22 (2008) 1075-1088